quemliclustat

Quemliclustat is a potent, selective small molecule inhibitor of CD73 (ecto-5'-nucleotidase), an enzyme responsible for the conversion of AMP to adenosine in the tumor microenvironment. By blocking CD73 activity, quemliclustat reduces extracellular adenosine levels and thereby diminishes adenosine-mediated immunosuppression. This action enhances anti-tumor immune responses by increasing the activity of cytotoxic T cells and natural killer (NK) cells while reducing suppressive immune cell populations such as myeloid-derived suppressor cells (MDSCs) and regulatory T lymphocytes (Tregs). Quemliclustat is being developed primarily for cancer indications including biliary tract cancer, pancreatic ductal adenocarcinoma, prostate cancer (metastatic castrate-resistant), upper gastrointestinal tract cancers, metastatic colorectal cancer, and other solid tumors. It is administered intravenously and remains investigational with clinical trials ongoing in multiple solid tumor settings.

Other names

2105904-82-1quemliclustat [USAN]